Shares of Natera Inc (NASDAQ:NTRA) have earned a consensus rating of “Buy” from the seven brokerages that are covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $42.00.
A number of research firms recently commented on NTRA. Piper Jaffray Companies set a $45.00 target price on shares of Natera and gave the stock a “buy” rating in a research note on Friday, October 11th. Craig Hallum lifted their target price on shares of Natera from $29.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. Cowen lifted their target price on shares of Natera from $30.00 to $42.00 and gave the stock an “average” rating in a research note on Friday. Canaccord Genuity reiterated a “buy” rating and issued a $44.00 target price on shares of Natera in a research note on Wednesday. Finally, ValuEngine cut shares of Natera from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd.
In other Natera news, CFO Michael Burkes Brophy sold 43,954 shares of Natera stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $29.00, for a total transaction of $1,274,666.00. Following the completion of the sale, the chief financial officer now directly owns 26,690 shares in the company, valued at approximately $774,010. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CTO Jonathan Sheena sold 1,033 shares of Natera stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $29.50, for a total transaction of $30,473.50. Following the sale, the chief technology officer now owns 241,937 shares of the company’s stock, valued at $7,137,141.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 438,947 shares of company stock valued at $13,888,596. Company insiders own 9.29% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Marshall Wace LLP purchased a new position in Natera during the 1st quarter valued at about $264,000. Focused Wealth Management Inc purchased a new position in shares of Natera in the 2nd quarter worth approximately $83,000. Moody Aldrich Partners LLC grew its position in shares of Natera by 16.9% in the 2nd quarter. Moody Aldrich Partners LLC now owns 50,491 shares of the medical research company’s stock worth $1,393,000 after buying an additional 7,286 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. purchased a new position in shares of Natera in the 2nd quarter worth approximately $278,000. Finally, AGF Investments Inc. grew its position in shares of Natera by 240.0% in the 2nd quarter. AGF Investments Inc. now owns 170,000 shares of the medical research company’s stock worth $4,689,000 after buying an additional 120,000 shares during the last quarter. Institutional investors and hedge funds own 94.95% of the company’s stock.
Shares of Natera stock traded up $0.52 on Thursday, reaching $38.51. The stock had a trading volume of 842,566 shares, compared to its average volume of 807,450. The company has a 50 day moving average price of $33.90 and a 200 day moving average price of $26.77. The company has a quick ratio of 2.42, a current ratio of 2.54 and a debt-to-equity ratio of 1.10. Natera has a 1 year low of $11.08 and a 1 year high of $39.53. The stock has a market capitalization of $2.66 billion, a P/E ratio of -17.91 and a beta of 1.42.
Natera (NASDAQ:NTRA) last released its earnings results on Wednesday, August 7th. The medical research company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.09. The company had revenue of $74.36 million during the quarter, compared to analysts’ expectations of $66.77 million. Natera had a negative net margin of 46.78% and a negative return on equity of 273.92%. Natera’s revenue for the quarter was up 17.9% on a year-over-year basis. During the same period last year, the business earned ($0.62) EPS. On average, analysts forecast that Natera will post -2.1 earnings per share for the current fiscal year.
Natera Company Profile
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Further Reading: Mutual funds are not immune from market timing
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.